Paeds Vivas · haematology-oncology-and-transfusion
Febrile neutropenia and infection in oncology: Viva
Branching clinical structured oral on febrile neutropenia and infection in the child with cancer. Covers the definition of fever in neutropenia and the absolute-neutrophil-count threshold, the first-hour empiric bundle and the door-to-antibiotic-in-under-sixty-minutes principle, the indications for adding vancomycin, the high-risk versus low-risk stratification that sets disposition and duration, the persistent-fever pathway and the empiric versus pre-emptive antifungal strategy, the management of a central-line infection and the line-removal decision, and the role of granulocyte colony-stimulating factor and antimicrobial prophylaxis.
On this page & tools
Target exams
Branch 1: Recognition and the first-hour bundle
The candidate must open by naming the syndrome in one sentence: a single temperature of 38.5 degrees Celsius or higher, or 38.0 degrees Celsius or higher sustained over one hour, in a child with an absolute neutrophil count under 0.5 times ten to the ninth per litre, is febrile neutropenia, and this child meets both thresholds (Lehrnbecher et al., J Clin Oncol 2017, PMID 28459614). The first action is to treat him as presumed bacteraemic, because the signs of sepsis are blunted when the neutrophil count is near zero and fever is often the only reliable signal. The candidate should state the absolute-neutrophil-count formula aloud: the white cell count multiplied by the percentage of segmented neutrophils plus bands, divided by one hundred. [2]
The examiner will press on the urgency. The candidate should cite the systematic review of Koenig and colleagues, which found that a shorter time to antibiotics is associated with better clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer, and should name the door-to-antibiotic target of under sixty minutes (Koenig et al., Support Care Cancer 2020, PMID 31264188). The UK audit of Morgan and Phillips documented that this first hour is still missed in a substantial fraction of children, so the candidate should stress that the blood cultures are drawn from every central-line lumen and peripherally before the dose, but they must never delay it. An avoidable delay here is an avoidable harm. [7]
The examiner will ask which empiric agent to give. The candidate should name an anti-pseudomonal beta-lactam as monotherapy, ceftazidime, piperacillin-tazobactam, cefepime, or meropenem, weight-dosed by the oncology protocol, because these cover Pseudomonas aeruginosa, which carries the highest mortality, alongside the common Gram-positive and Gram-negative organisms (Freifeld et al., Clin Infect Dis 2011, PMID 21258094). The candidate should then give the indications for adding vancomycin: suspected line infection, a serious soft-tissue or pulmonary focus, mucositis, haemodynamic instability, severe sepsis, or known colonisation with methicillin-resistant Staphylococcus aureus. Routine empiric vancomycin is not recommended because it adds nephrotoxicity without a mortality benefit. [1]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]Freifeld AG, Bow EJ, Sepkowitz KA, et al Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 2011.PMID 21258094
- [2]Lehrnbecher T, Robinson P, Fisher B, et al Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol, 2017.PMID 28459614
- [6]Ammann RA, Bodmer N, Hirt A, et al Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol, 2010.PMID 20231680
- [7]Koenig C, Schneider C, Morgan JE, et al. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer, 2020.PMID 31264188
- [11]Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. J Antimicrob Chemother, 2018.PMID 30010931